文献速递淋巴瘤

AP-1-BATF与BATF3模块对间变性大细胞淋巴瘤的生长、存活及TH17/ILC3偏移至关重要

The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma.
PubMed 文献 · Leukemia · 2018-03-28

研究显示ALK+与ALK-间变性大细胞淋巴瘤(ALCL)中BATF与BATF3高表达,与AP-1及IRF4共占复合元件,基因失活或AP-1抑制可致ALCL体内外生长阻滞和/或死亡。AP-1-BATF模块建立TH17/3型先天淋巴样细胞(ILC3)相关基因表达,部分ALK+ ALCL儿童IL-17A/IL-17F升高,原发淋巴瘤数据分析证实ALCL较PTCL偏向TH17尤其ILC3。RORC药理抑制单药致ALCL细胞系死亡,与克唑替尼联用强化ALK+ ALCL死亡诱导。

要点

  • BATF与BATF3在ALCL高表达,与AP-1及IRF4共占复合元件,区别于非ALCL。
  • BATF基因失活或全局AP-1抑制导致ALCL体外及体内生长阻滞和/或细胞死亡。
  • RORC抑制单药致ALCL细胞系死亡,与克唑替尼联用增强ALK+ ALCL死亡诱导。

核心结论

  • AP-1/BATFs在ALCL中起关键作用,并引出部分ALCL可能起源于ILC3的概念。

研究设计与样本

  • 研究采用ALCL细胞系、体内模型及原发淋巴瘤数据分析,评估BATF/BATF3表达、基因失活与药物抑制效应。

主要发现

  • BATF和BATF3在ALCL高表达,结合经典AP-1基序并与ALCL中失调的AP-1因子相互作用。
  • BATFs与IRF4共占AP-1-IRF复合元件,可将ALCL与非ALCL区分。
  • BATFs基因特异性失活或全局AP-1抑制导致ALCL体外和体内生长阻滞和/或细胞死亡。
  • AP-1-BATF模块在ALCL细胞中建立TH17/ILC3相关基因表达,包括AHR、IL17F、IL22、IL26、IL23R和RORγt等标志基因。
  • 部分ALK+ ALCL儿童和青少年中检测到IL-17A和IL-17F水平升高;原发淋巴瘤数据分析证实ALCL较PTCL偏向TH17尤其ILC3。

关键数值与推荐

  • RORC药理抑制单药导致ALCL细胞系细胞死亡,与ALK抑制剂克唑替尼联用强化ALK+ ALCL的死亡诱导。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Transcription factor AP-1 is constitutively activated and IRF4 drives growth and survival in ALK+ and ALK- anaplastic large cell lymphoma (ALCL). Here we demonstrate high-level BATF and BATF3 expression in ALCL. Both BATFs bind classical AP-1 motifs and interact with in ALCL deregulated AP-1 factors. Together with IRF4, they co-occupy AP-1-IRF composite elements, differentiating ALCL from non-ALCL. Gene-specific inactivation of BATFs, or global AP-1 inhibition results in ALCL growth retardation and/or cell death in vitro and in vivo. Furthermore, the AP-1-BATF module establishes TH17/group 3 innate lymphoid cells (ILC3)-associated gene expression in ALCL cells, including marker genes such as AHR, IL17F, IL22, IL26, IL23R and RORγt. Elevated IL-17A and IL-17F levels were detected in a subset of children and adolescents with ALK+ ALCL. Furthermore, a comprehensive analysis of primary lymphoma data confirms TH17-, and in particular ILC3-skewing in ALCL compared with PTCL. Finally, pharmacological inhibition of RORC as single treatment leads to cell death in ALCL cell lines and, in combination with the ALK inhibitor crizotinib, enforces death induction in ALK+ ALCL. Our data highlight the crucial role of AP-1/BATFs in ALCL and lead to the concept that some ALCL might originate from ILC3.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Schleussner N, Merkel O, Costanza M, et al. The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma. Leukemia. 2018. PMID: 29588546. doi:10.1038/s41375-018-0045-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。